Grail has initiated the REACH study, which focuses on 50,000 Medicare beneficiaries receiving routine care along with an annual Galleri test. The Galleri test is a multi-cancer panel designed to detect early and asymptomatic cancer, leading to earlier treatment and improved survival rates.
Currently, the US only recommends five cancer screenings, resulting in missed early cancer diagnoses. The REACH study combines innovative early cancer screening with research in underrepresented patient populations. An emphasis on the importance of conducting clinical trials is needed to establish knowledge and provide necessary healthcare in underserved communities.
The REACH study focuses on two aspects: implementing early multi-cancer screening as a standard of care and studying patients in the US Medicare system. This trial aims to not only improve the accuracy of the Galleri test but also understand the impact of early cancer screening on the global standard of care.
7 out of 10 US cancer deaths are among Medicare beneficiaries
The US National Institutes of Health has reported that a significant number of cancer-related deaths occur in individuals aged 65 and older, with a majority of these cases being diagnosed within the US Medicare system and 7 out of 10 cancer deaths are among Medicare beneficiaries. By implementing asymptomatic and early cancer screening, mortality rates can be significantly reduced as individuals will receive necessary care earlier for a wider range of cancers.
Many clinical trials do not focus on recruiting from underserved communities and thus patient backgrounds remain homogenous in nature. Thus, the REACH study furthers our understanding of the Medicaid/Medicare population and how the medical system can better serve those most at risk.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
<!–
–>
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.medicaldevice-network.com/analyst-comment/grail-reach-trial-early-detection/